Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Failed Attempts: Multiple drugs (Selonsertib, Cenicriviroc, Elafibranor) failed Phase 3 NASH trials because they: Targeted single pathways (inflammation or fibrosis) Didn't address root cause (obesity, insulin resistance) Showed biomarker improvements but not biopsy-proven NASH resolution Retatrutide's Advantage: Addresses root metabolic dysfunction (28.7% weight loss) Proven up to 82.4% liver fat reduction (Phase 2a) Inflammation resolution (enzyme normalization) Multi-pathway hepatic benefits Probability of Success: Higher than previous NASH drug candidates, but biopsy-proven efficacy still needs confirmation
This synergy ensures that while you're gaining control over your appetite, you aren't sacrificing the vitality you need for work, exercise, and just feeling great every day
Small, frequent meals keep the stomach from overloading while maintaining adequate caloric and nutritional intake
doi: 10.1016/j.biopsych.2016.05.005 116 LennoxR.PorterD
However, this area is recently attracting more attention with the development of wearable medical devices like continuous glucose monitoring systems (CGM)
To view or add a comment, sign in Every Mechanism Has a Safety Story The more I study LDL-lowering drugs, the more I realize each one has its own safety story
